Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Not yet recruiting
Merck Sharp & Dohme LLC
Phase 2
2022-08-05
The primary objective is to evaluate in participants with high-grade serous ovarian cancer
(HGSOC), whether the reduction from baseline in circulating tumor DNA (ctDNA) at Cycle 3
(ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with
standard of care (SOC) therapy than in those receiving pembrolizumab + SOC therapy.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Recruiting
Neonc Technologies, Inc.
Phase 1/Phase 2
2023-11-01
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety,
pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of
patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma
IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of
NEO212 when given with select SOC for the treatment of solid tumor patients with
radiographically confirmed uncontrolled brain metastasis. The study will have three phases,
Phase 1, Phase 2a and Phase 2b.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
